Guidant issues second consecutive performance warning
This article was originally published in Clinica
Guidant has warned that its fourth-quarter revenues will be below analysts' estimates and that its earnings per share will be down by between two and three cents as a result. Analysts were expecting earnings of 43 cents a share, compared with 36 cents a year ago. The announcement follows a similar warning by the company in October for its third-quarter sales (see Clinica No 929, p 13).
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.